

Roberta Maltoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7356205/publications.pdf>

Version: 2024-02-01

70
papers

1,199
citations

430442

18
h-index

414034

32
g-index

71
all docs

71
docs citations

71
times ranked

2085
citing authors

#	ARTICLE	IF	CITATIONS
1	Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study. <i>Current Oncology</i> , 2022, 29, 433-438.	0.9	1
2	Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab. <i>Scientific Reports</i> , 2022, 12, 3385.	1.6	4
3	The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 503-509.	0.7	7
4	CAR T cells targeting options in the fight against multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 37-45.	0.2	2
5	Case Report: Analysis of Circulating Tumor Cells in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient. <i>Frontiers in Medicine</i> , 2021, 8, 689895.	1.2	4
6	Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue. <i>Biomedicines</i> , 2021, 9, 1242.	1.4	6
7	Early Detection and Investigation of Extracellular Vesicles Biomarkers in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 732900.	1.6	4
8	Obesity and Dose of Anti-cancer Therapy: Are We Sure to Be on the Right Track in the Precision Medicine Era?. <i>Frontiers in Medicine</i> , 2021, 8, 725346.	1.2	0
9	Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls. <i>Journal of Personalized Medicine</i> , 2021, 11, 1211.	1.1	10
10	The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 772216.	1.8	3
11	Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer. <i>Annals of Translational Medicine</i> , 2021, 10, 0-0.	0.7	1
12	Obesity and Dose of Anti-cancer Therapy: Are We Sure to Be on the Right Track in the Precision Medicine Era?. <i>Frontiers in Medicine</i> , 2021, 8, 725346.	1.2	3
13	Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer?. <i>Breast Journal</i> , 2020, 26, 739-742.	0.4	10
14	Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold. <i>Diagnostic Pathology</i> , 2020, 15, 109.	0.9	1
15	Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC Letter. <i>Clinical Cancer Research</i> , 2020, 26, 3892-3893.	3.2	1
16	miR-9-5p as a Regulator of the Androgen Receptor Pathway in Breast Cancer Cell Lines. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 579160.	1.8	15
17	Are we ready to use TMB in breast cancer clinical practice?. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1943-1945.	2.0	15
18	Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer. <i>Cancers</i> , 2020, 12, 2490.	1.7	25

#	ARTICLE	IF	CITATIONS
19	Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience. <i>Diagnostics</i> , 2020, 10, 573.	1.3	13
20	Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer. <i>Medicine (United States)</i> , 2020, 99, e20396.	0.4	1
21	Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer?. <i>Clinical Breast Cancer</i> , 2020, 20, 359-360.	1.1	1
22	The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a <i>post hoc</i> analysis of the IBIS 3 trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591988899.	1.4	7
23	Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer. <i>Cell Transplantation</i> , 2020, 29, 096368972092505.	1.2	5
24	Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 517-521.	0.3	1
25	<p>Single shot ultrasound-guided thoracic paravertebral block for opioid-free radical mastectomy: a prospective observational study</p>. <i>Journal of Pain Research</i> , 2019, Volume 12, 2701-2708.	0.8	17
26	What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 231-232.	1.1	1
27	Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?. <i>Journal of Oncology</i> , 2019, 2019, 1-6.	0.6	10
28	CD68, CD163, and matrix metalloproteinase 9 (MMP-9) in breast tumor microenvironment to predict breast cancer survival: are they enough?. <i>Breast Cancer Research</i> , 2019, 21, 49.	2.2	1
29	The prognostic role of progesterone receptor in patients with rapidly proliferating, hormone receptor-positive early breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 545-545.	0.8	1
30	Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?. <i>BMC Cancer</i> , 2018, 18, 348.	1.1	25
31	Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence. <i>Cancer Management and Research</i> , 2018, Volume 10, 3083-3099.	0.9	21
32	Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. <i>Annals of Oncology</i> , 2018, 29, 2328-2333.	0.6	124
33	Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?. <i>Translational Oncology</i> , 2018, 11, 950-956.	1.7	24
34	Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?. <i>Frontiers in Endocrinology</i> , 2018, 9, 137.	1.5	13
35	Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 863-871.	1.1	14
36	Sorafenib for the treatment of breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 621-630.	0.9	29

#	ARTICLE	IF	CITATIONS
37	Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma <i>in situ</i> treated with surgery and radiotherapy. <i>International Journal of Experimental Pathology</i> , 2017, 98, 289-295.	0.6	14
38	Progress with palbociclib in breast cancer: latest evidence and clinical considerations. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 83-105.	1.4	45
39	Cell-free DNA detected by <i>liquid biopsy</i> as a potential prognostic biomarker in early breast cancer. <i>Oncotarget</i> , 2017, 8, 16642-16649.	0.8	29
40	Is androgen receptor useful to predict the efficacy of anti-estrogen therapy in advanced breast cancer?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1042-1042.	0.8	1
41	CTCs in early breast cancer: A path worth taking. <i>Cancer Letters</i> , 2016, 376, 205-210.	3.2	28
42	Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 79-86.	1.1	20
43	Androgen receptor signaling pathways as a target for breast cancer treatment. <i>Endocrine-Related Cancer</i> , 2016, 23, R485-R498.	1.6	78
44	A phase Ib study of lapatinib plus pegylated liposomal doxorubicin in patients with advanced HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 600-600.	0.8	1
45	Cell-free DNA detected by <i>liquid biopsy</i> as a potential prognostic biomarker in patients with different subtypes of breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23081-e23081.	0.8	1
46	Role of Androgen and Estrogen Receptors as Prognostic and Potential Predictive Markers of Ductal Carcinoma <i>in Situ</i> of the Breast. <i>International Journal of Biological Markers</i> , 2015, 30, 425-428.	0.7	14
47	Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 57-65.	1.1	16
48	Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 1874-1881.	1.3	20
49	Circulating tumor cells in early breast cancer: A connection with vascular invasion. <i>Cancer Letters</i> , 2015, 367, 43-48.	3.2	34
50	Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1647-1663.	1.5	10
51	New Biomarkers to Predict the Evolution of <i>In Situ</i> Breast Cancers. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	10
52	Benefit from anthracyclines in relation to biological profiles in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 307-318.	1.1	18
53	Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy. <i>Tumori</i> , 2014, 100, e79-82.	0.6	2
54	RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study. <i>International Journal of Molecular Sciences</i> , 2013, 14, 10683-10693.	1.8	15

#	ARTICLE	IF	CITATIONS
55	Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. <i>Heart</i> , 2013, 99, 634-639.	1.2	89
56	Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 775-784.	1.1	19
57	A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 871-876.	1.1	3
58	Phase I Study of Paclitaxel and Uracil plus Tegafur Combination in Patients with Pretreated Metastatic Breast Cancer: Drug Sequencing Based on Preclinical Modelling Studies. <i>Oncology</i> , 2007, 72, 118-124.	0.9	8
59	Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience. <i>BMC Cancer</i> , 2006, 6, 76.	1.1	11
60	Do Serum Angiogenic Growth Factors Provide Additional Information to That of Conventional Markers in Monitoring the Course of Metastatic Breast Cancer?. <i>Tumor Biology</i> , 2006, 27, 302-308.	0.8	9
61	Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines. <i>Breast Cancer Research</i> , 2005, 7, R681-9.	2.2	63
62	Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2001, 68, 101-110.	1.1	6
63	Tumor Infiltrating Lymphocytes and Continuous Infusion Interleukin-2 after Metastasectomy in 61 Patients with Melanoma, Colorectal and Renal Carcinoma. <i>Tumori</i> , 2000, 86, 46-52.	0.6	17
64	Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients. <i>Cancer Immunology, Immunotherapy</i> , 1998, 46, 185-193.	2.0	21
65	Intraperitoneal Carboplatin with or without Interferon-Î± in Advanced Ovarian Cancer Patients with Minimal Residual Disease at Second Look: A Prospective Randomized Trial of 111 Patients. <i>Gynecologic Oncology</i> , 1997, 65, 499-505.	0.6	30
66	Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study. <i>Breast Cancer Research and Treatment</i> , 1997, 43, 7-14.	1.1	60
67	Liver Metastases from Gastric Carcinoma: Report of a Patient Treated with Adoptive Immunotherapy (Tumor-Infiltrating Lymphocytes plus Interleukin-2 and Subsequently Local-Regional) <i>Tj ETQq1 1 0.784314 rgBT /Oædock 10i Tf 50 25</i>		
68	Clinical prediction of survival is more accurate than the Karnofsky performance status in estimating life span of terminally ill cancer patients. <i>European Journal of Cancer</i> , 1994, 30, 764-766.	1.3	79
69	EAP in advanced gastric cancer. <i>European Journal of Cancer</i> , 1993, 29, 1219-1220.	1.3	0
70	Evaluation of Toxicity in 22 Patients Treated with Subcutaneous Interleukin-2, Alpha-Interferon with and without Chemotherapy. <i>Journal of Chemotherapy</i> , 1992, 4, 394-398.	0.7	6